Home » Insmed’s Brensocatib Enters Trial as Possible COVID-19 Treatment
Insmed’s Brensocatib Enters Trial as Possible COVID-19 Treatment
Insmed is sponsoring a clinical trial in the UK of its bronchial drug Brensocatib as a potential COVID-19 treatment.
Designated urgent by the UK's National Institute for Health Research, the trial will include up to 300 patients at 10 sites.
Patients enrollment is expected to begin in May.
Upcoming Events
-
18Jul
-
21Oct